This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carel, J.-C. Articles by Chaussain, J.-L. Search for Related Content PubMed PubMed Citation Articles by Carel, J.-C. Articles by Chaussain, J.-L.

Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment

Department of Pediatric Endocrinology (J.-C.C., J.-L.C.) and Laboratoire de Biochimie Hormonale (M.R., N.L.), and INSERM U-342 (J.-C.C., J.-L.C., M.R., N.L.), Hôpital Saint Vincent de Paul, 75014 Paris; and IPSEN-BIOTECH Laboratories (S.I., F.T., J.B.), 75014 Paris, France

Address all correspondence and requests for reprints to: Dr. Jean-Claude Carel, INSERM U-342, Hôpital Saint Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, France. E-mail: carel{at}cochin.inserm.fr

The impact of treatment of central precocious puberty (CPP) with GnRH agonists on final statural height (FH) remains controversial, and guidelines on the optimal time point for interruption of these treatments have not been established. We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patients not treated with GnRH agonist. The FH SD score was close to 0 and was not different from the genetic target height. In girls, FH was improved by 4.8 ± 5.8 cm compared with predicted height before treatment and by 8.3 cm by comparison with a historical group. In boys, comparison with a historical group revealed a 13.7-cm improvement, whereas predicted height before treatment was similar to FH. Three variables were independently associated with FH in girls: the bone age/statural age ratio at the onset of treatment (negatively), the height SD score at the end of treatment, and the posttreatment growth spurt ( FH - height at the end of treatment). The influence of the posttreatment growth spurt, itself dependent on age and bone age at the interruption of treatment, suggests that continuing treatment beyond the age of 11 yr in girls does not improve and could actually decrease FH. This point should be evaluated in a formal controlled trial.

This article has been cited by other articles:

				V. N. Brito, A. C. Latronico, P. Cukier, M. G. Teles, L. F. G. Silveira, I. J. P. Arnhold, and B. B. Mendonca Factors Determining Normal Adult Height in Girls with Gonadotropin-Dependent Precocious Puberty Treated with Depot Gonadotropin-Releasing Hormone Analogs J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2662 - 2669. [Abstract] [Full Text] [PDF]

				J.-C. Carel and J. Leger Precocious Puberty N. Engl. J. Med., May 29, 2008; 358(22): 2366 - 2377. [Full Text] [PDF]

				A. M. Pasquino, I. Pucarelli, F. Accardo, V. Demiraj, M. Segni, and R. Di Nardo Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive Function J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 190 - 195. [Abstract] [Full Text] [PDF]

				J.-C. Carel, J. Blumberg, C. Seymour, C. Adamsbaum, N. Lahlou, and for the Triptorelin 3-month CPP Study Group Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty Eur. J. Endocrinol., January 1, 2006; 154(1): 119 - 124. [Abstract] [Full Text] [PDF]

				T. Tanaka, H. Niimi, N. Matsuo, K. Fujieda, K. Tachibana, K. Ohyama, M. Satoh, and K. Kugu Results of Long-Term Follow-Up after Treatment of Central Precocious Puberty with Leuprorelin Acetate: Evaluation of Effectiveness of Treatment and Recovery of Gonadal Function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1371 - 1376. [Abstract] [Full Text] [PDF]

				J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain Precocious puberty and statural growth Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147. [Abstract] [Full Text] [PDF]

				J.-C. Carel, N. Lahlou, O. Jaramillo, V. Montauban, C. Teinturier, M. Colle, C. Lucas, and J. L. Chaussain Treatment of Central Precocious Puberty by Subcutaneous Injections of Leuprorelin 3-Month Depot (11.25 mg) J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4111 - 4116. [Abstract] [Full Text] [PDF]

				L. Lazar, R. Kauli, A. Pertzelan, and M. Phillip Gonadotropin-Suppressive Therapy in Girls with Early and Fast Puberty Affects the Pace of Puberty but Not Total Pubertal Growth or Final Height J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2090 - 2094. [Abstract] [Full Text] [PDF]

				M. Lampit, A. Golander, H. Guttmann, and Z.'e. Hochberg Estrogen Mini-Dose Replacement during GnRH Agonist Therapy in Central Precocious Puberty: A Pilot Study J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 687 - 690. [Abstract] [Full Text] [PDF]

				K. O. Klein, K. M. Barnes, J. V. Jones, P. P. Feuillan, and G. B. Cutler Jr. Increased Final Height in Precocious Puberty after Long-Term Treatment with LHRH Agonists: The National Institutes of Health Experience J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4711 - 4716. [Abstract] [Full Text] [PDF]

				L. Lazar, A. Pertzelan, N. Weintrob, M. Phillip, and R. Kauli Sexual Precocity in Boys: Accelerated Versus Slowly Progressive Puberty Gonadotropin-Suppressive Therapy and Final Height J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4127 - 4132. [Abstract] [Full Text] [PDF]

				G. A. Kamp, D. Mul, J. J. J. Waelkens, M. Jansen, H. A. Delemarre-van de Waal, L. Verhoeven-Wind, M. Frolich, W. Oostdijk, and J. M. Wit A Randomized Controlled Trial of Three Years Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Children with Idiopathic Short Stature and Intrauterine Growth Retardation J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2969 - 2975. [Abstract] [Full Text] [PDF]

				Long-Term Outcome after Depot Gonadotropin-Releasing Hormone Agonist Treatment of Central Precocious Puberty: Final Height, Body Proportions, Body Composition, Bone Mineral Density, and Reproductive Function J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4583 - 4590. [Abstract] [Full Text]